Thank you for subscribing!

A Disruptive Company, Elevating the Industry to New Highs

How This Cannabis Player is Making Superior Products at Reduced Cost

Grapefruit USA, Inc. (OTCQB: GPFT) is a fully licensed cannabis manufacturer and distributor in the legal cannabis marketplace, with its own patented and branded line of products, including the disruptive Hourglass™ time release THC+CBD delivery cream. Grapefruit experienced remarkable growth in 2020, increasing revenue by 714% YoY, and we believe that trend will continue in 2021.

“Once we do have federal legalization, Grapefruit is in a position to go not only nationally, but internationally,” Grapefruit CEO Bradley Yourist said this summer.

Find out more at Grapefruit

Why Invest In Grapefruit?

  • Unique Products Grapefruit offers a variety of premier products, the most exciting being their patented Hourglass™ Time Release THC+CBD Delivery Cream. It solves the inherent problems of absorbing THC through the skin, and is a truly disruptive product in the cannabis space, creating a third delivery option for THC. 
  • Scientific Approach – The research and development arm of Grapefruit is truly dedicated. Their breakthrough with Hourglass™ led to the creation of the first and only topical cream that breaks the blood brain barrier. This level of testing and care extends to all the products in Grapefruits portfolio, and we’re excited to see what they come up with next. 
  • Cost-Saving – Grapefruit owns a manufacturing facility in Desert Hot Springs, California, where the manufacture of THC Honey Oil, a substance used across all their various products, is not taxed. This gives Grapefruit a competitive edge in the cannabis landscape. 
  • Growing Market The global cannabis market is expected to grow to $97.35 billion by 2026, expanding at a CAGR of 32.92%.
  • Explosive Revenue – Grapefruit’s 2020 revenues increased by 714% YoY, to $3.67 million. With continued expansion of their bulk flower distribution and the popularity of their topical cream, 2021 could be even bigger than last year. Over the last three years, Grapefruit averaged a 350% increase in revenue. We think continued growth is probable, considering the current political climate and attitudes toward cannabis. 
  • Great Name – Seriously. How many different variations of Canna, Hemp, or Green can you remember? Grapefruit is a simple, memorable moniker that has a nice ring to it. Don’t overlook a good name. 
  • Responsible Management – The team behind Grapefruit has made thoughtful decisions regarding the placement of manufacturing, the direction of R&D, and the expansion of distribution partners. We don’t think that the success with Hourglass is a one-off; it’s an indicator of what they can do with a little capital.


All the Benefits of Cannabis, None of the Drawbacks of Smoking


“A High You Can Trust”

That’s Grapefruit’s motto. It embodies their commitment to high-quality, natural, pesticide-free products and production methods. They are on a mission to deliver a consistent and dependable premium cannabis to discerning customers.

Judging by their massive spike in revenue, we believe they are living up to their motto.

With a 714% YoY revenue increase, the release of a patented topical product, and continued expansion of bulk distribution, Grapefruit is in good shape. Headquartered in Los Angeles, California, they have held licensing for manufacturing and distributing cannabis since 2018, and they own and operate a licensed cannabis extraction laboratory and a licensed wholesale distribution facility.


The Star Technology

Hourglass™ Topical Delivery Cream

Grapefruit’s patented Hourglass™ topical delivery cream has solved the previously insurmountable difficulties of efficient skin absorption of THC and other cannabinoids. 

It allows users to experience a sustained and holistic delivery of THC/cannabinoids, by creating the “patchless patch,” a patch-like layer of cream that lodges in the top layer of the skin and releases over time. Additional applications may be made confidently at the user’s discretion. 

This is the only product on the planet which successfully utilizes a patented time release THC and CBD delivery mechanism to deliver the holistic benefits of cannabis to those who need it.*

Hourglass™ is a unique, highly concentrated full spectrum time-release topical delivery cream that delivers a holistic amount of THC, along with a wide range of other cannabinoids (or just CBD), over a four- to eight-hour period.* The formula comes off through the natural sloughing process of dead skin cells. Hourglass provides many holistic benefits, all of which promote health and wellness as it’s number one goal.

The cream provides users with an entourage effect of THC plus a wide range of cannabinoids, including CBD, Cannabinol (CBN), Cannabigerol (CBG), Delta-8, Tetrahydrocannabivarin (THCV), and Cannabielsoin (CBE) via a proprietary Patchless Patch™ system. 

Grapefruit’s breakthrough technology has fundamentally changed the way individuals can use THC and cannabinoids for holistic benefits.* As a result, smoking cannabis or hemp flowers and orally consuming edibles, which are metabolized in the gut and liver resulting in uneven reactions, are no longer the only ways to receive the benefits of THC/cannabinoids.* For the first time in history, there is an effective, easy to use third choice.

*This product is not regulated by the FDA and is not intended to cure, mitigate, treat or prevent disease.


Hourglass™ CBD Delivery Cream

As mentioned, the Hourglass™ technology can be applied to different products. This led to Grapefruit introducing the world’s first patented time-release, hemp-based CBD topical cream with boosted bioavailability. 

To this point, non-THC creams on the market have been applied to the skin and enter the body with a “barrage” effect. The body is only able to absorb the benefits of even the highest quality CBD creams in a short window. 

Grapefruit’s Hourglass™ technology, however, grinds CBD into nano sized particles smaller than the width of a human hair, which allows for much higher bioavailability and absorption that sustains over a 4 to 8 hour period. 

“Over the last several months, our Hourglass™ product team has received extremely positive product feedback and internal reviews from our product testers and retail customers after their regular use of our hemp-based CBD Hourglass™ topicals, which is extremely gratifying for the company and at base shows that the technology works,” said Bradley Yourist, CEO at Grapefruit USA. “Grapefruit’s Hourglass™ Topical Delivery Cream will fundamentally change the way individuals use CBD and other cannabinoids to obtain their holistic benefits.”

To purchase Grapefruit’s ground-breaking CBD only delivery cream, please visit the Hourglass™ website.

Expanding Their Reach

In 2021, Grapefruit expanded its Hourglass™ distribution potential by securing a distribution deal with a popular California retailer as well as an agreement to bring the patented technology into Canada.

First, the company announced that Captor Capital Corp. would begin to feature GPFT’s Hourglass™ Time Release THC+CBD Delivery Topical Relief Cream in their retail locations. It was a major breakthrough for Grapefruit, which had been eager to release a revolutionary product but hampered by pandemic-caused retail disruptions.

“Over the last 15 months, Grapefruit has been hampered from effectively distributing our Hourglass topical relief cream to new retail cannabis outlets due to the COVID-19 lockdown. Now that the lockdown is over, GPFT is able to effectively distribute Hourglass products throughout California.”Bradley J. Yourist, Grapefruit’s CEO and co-founder said. “We believe the Captor deal is only the start of a trend that will allow Grapefruit to quickly grow Hourglass brand awareness and Grapefruit revenues. We know the patented Hourglass time-release topical delivery system not only works effectively but is the most effective in the world.”

Clearly not one to rest on its laurels, the team at Grapefruit then proceeded to secure an agreement with a Canadian distributor. The Expanded Agreement with Canadian Firms Medz Cannabis and 6PAK Solutions allowed Grapefruit to file it’s Notice of New Cannabis Product (NNCP) with Health Canada. Upon approval, Medz Cannabis will act as Grapefruit’s licensed Canadian distributor, with plans for distribution to begin the second quarter of 2022.

All signs point to Grapefruit and Hourglass becoming a familiar, widely recognized brand in North America very soon.

Areas of Business

Grapefruit is involved in multiple areas of cannabis distribution and production; from their own proprietary products, to serving other licensed cannabis businesses. These products and services include:

  • Distribution Grapefruit distributes all-things cannabis throughout California, specializing in bulk AAA exotic indoor flowers sourced from in-state farms. The wholesale distribution arm facilitates flowers, both fresh and dry frozen, and bulk oil transactions.  
  • Manufacturing The company owns and operates a fully licensed and compliant ethanol extraction lab that produces a high-quality distillate, THC Honey Oil. This distillate is used in infused edibles, tinctures, creams and even vape cartridges. 
  • Hourglass™ Topical THC+CBD Delivery Cream The company’s patented Hourglass™ Topical Delivery Cream has solved the inherent difficulties of efficient skin absorption of THC and cannabinoids such as CBD, CBN, CBG and CBC, as well as hemp-derived CBDs and cannabinoids. Hourglass™ is a transformative delivery technology which fundamentally changes the way individuals will use THC and CBD.
  • Rainbow Dreams Rainbow Dreams is the company’s lifestyle brand designed for the recreational cannabis marketplace. This brand captures the spirit of the 1970s and offers vape carts with unique cannabis strains and natural flavors. The product fulfills an important marketplace niche – a top-shelf product that is competitively priced.


Recent Press Releases



Bradley J. Yourist

Chief Executive Officer

Bradley J. Yourist is the CEO of Grapefruit, a licensed cannabis branding, distribution and manufacturing company in the State of California. He has seen the medical cannabis market grow from its infancy in the 1990s, and has a deep understanding of its ins and outs. He has seen how Cannabinoids have mitigated the effects of autism, epilepsy, cancer, glaucoma, and chemotherapy induced nausea. This first hand experience led him to promote the use of medical cannabis to assist patients in need. He truly believes the thoughtful use of cannabis products can help bring health to the world.


Daniel J. Yourist

Chief Operating Officer  

Daniel J. Yourist is Chief Operating Officer of Grapefruit USA. He is a California licensed attorney and Real Estate Broker, as well as a licensing expert in the cannabis space. Mr. Yourist has extensive experience in managing a California Cannabis business – from sourcing purchasing and selling compliant cannabis goods to retailers, to ensuring compliance with State and Local Cannabis Laws and Regulations. He aims to bring clarity to the regulatory atmosphere of cannabis, and working knowledge of the operational aspects of the Distribution and Manufacturing components of Grapefruit to the entire team.




Who are we and what do we do? We are paid advertisers, also known as stock touts or stock promoters, who disseminate favorable information (the “Information”) about publicly traded companies (the “Profiled Issuers”). How is the Information published? We publish the Information on our Website, in newsletters, audio services, live interviews, featured “research” reports, on message boards and in email communications for specific time periods that are agreed upon between us and the Profiled Issuer or third party paying us. Our publication of the Information is known as a “Campaign”. Will everyone receive the Information at the same time? No. The Information may be sent to potential investors at different times that are minutes, hours, days or even weeks apart. How is a potential investor impacted if he receives the Information later than other investors? Typically, the trading volume and price of a Profiled Issuer’s securities increases after the Information is provided to the first group of investors. Therefore, the later an investor receives the Information, the more likely it is that he will suffer increased trading losses if he purchases the securities of a Profiled Issuer. What will happen to the shares that we hold during the Campaign? We will sell the shares we hold while we tell investors to purchase during the Campaign. What will happen when the Campaign ends? Most, if not all, of the Profiled Issuers are penny stocks that are illiquid and whose securities are subject to wide fluctuations in trading price and volume. During the Campaign the trading volume and price of the securities of each Profiled Issuer will likely increase significantly. When the Campaign ends, the volume and price of the Profiled Issuer will likely decrease dramatically. As a result, investors who purchase during the Campaign and hold shares of the Profiled Issuer when the Campaign ends will probably lose most, if not all, of their investment. Why do we publish only favorable Information? We only publish favorable information because we are compensated to publish only favorable information. Why don’t we publish negative Information? We don’t publish negative information because we are not paid to publish negative information. We are paid to publish only favorable information. Is the Information complete, accurate, truthful or reliable? No. The Information is a snapshot that provides only positive information about the Profiled Issuers. The Information consists of only positive content. We do not and will not publish any negative information about the Profiled Issuers; accordingly, investors should consider the Information to be one-sided and not balanced, complete, accurate, truthful or reliable. What we do not do? We do not publish negative information about the Profiled Issuers. We do not verify or confirm any portion of the Information. We do not conduct any due diligence, nor do we research any aspect of the Information including the completeness, accuracy, truthfulness or reliability of the Information. We do not review the Profiled Issuers’ financial condition, operations, business model, management or risks involved in the Profiled Issuer’s business or an investment in a Profiled Issuer’s securities. Where does the Information come from? The Information is provided to us by the Profiled Issuers and/or the person who hires us. We may also obtain the Information from publicly available sources such as the OTC Markets, Google, NASDAQ, NYSE, the Securities and Exchange Commission’s Edgar database or other available public sources. If we say we make “stock picks,” are those picks our own? No, they are not. We are compensated to advertise the securities we are told to advertise. What will happen if an investor relies on the Information? If an investor relies on the Information in making an investment decision it is highly probable that the investor will lose most, if not all, of his or her investment. Investors should not rely on the Information to make an investment decision. Who pays us to publish the Information? The source of our compensation varies depending upon the particular circumstances of the Campaign. We are compensated by the Profiled Issuers, third party shareholders and other parties related to the Profiled Issuers such as officers and/or directors who will derive a financial or other benefit from an increase in the trading price and/or volume of a Profiled Issuer’s securities. The nature and amount of compensation we receive for publishing the Information about each Profiled Issuer and our ownership of each Profiled Issuer is set forth below under the heading captioned, “What we are compensated”. What warranties do we make about the Information? None. We make no warranty or representation about the Information, including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable and as such, your use of the Information is at your own risk. The Information is provided as is without limitation. What we are not. We are not and do not act in the capacity of any of the following; as such, you should not construe our activities as involving any of the following:
  • An independent adviser or consultant;
  • A fortune teller;
  • An investment adviser or an entity engaging in activities that would be deemed to be providing investment advice that requires registration either at the federal or state level;
  • A broker-dealer or an individual acting in the capacity of a registered representative or broker;
  • A stock picker;
  • A securities trading expert;
  • A securities researcher or analyst;
  • A financial planner or one who engages in financial planning;
  • A provider of stock recommendations;
  • A provider of advice about buy, sell or hold recommendations as to specific securities; or
  • An agent offering or securities for sale or soliciting their purchase.
Are risks in this disclaimer the only risks investors should be aware of? No. There are numerous risks associated with each Profiled Issuer and investors should undertake a full review of each Profiled Issuer with the assistance of their financial, legal, and tax advisers prior to purchasing the securities of any Profiled Issuer. What conflicts of interest do we have in publishing the Information? We are not objective or independent and have multiple conflicts of interest. The Profiled Issuers and parties hiring us have conflicts of interest. What will happen to the shares that we hold during the Campaign? We will sell the shares we hold while we tell investors to purchase. Our publication of the Information involves actual and material conflicts of interest including but not limited to the following:
  • We receive monetary and/or securities compensation in exchange for publishing the (favorable) Information about the Profiled Issuers;
  • We do not publish any negative information whatsoever about the Profiled Issuers;
  • We may own a Profiled Issuer’s securities that we acquired from the Profiled Issuer, third parties or from our own open market purchases before, during or after the Campaign and we may sell these securities during the Campaign while publishing the (favorable) information that instructs investors to purchase. Our selling of a Profiled Issuer’s securities will likely cause investors to suffer losses;
  • A short time after we acquire a Profiled Issuer’s securities, we may publish the (favorable) Information about the Profiled Issuer advising others, including you, to purchase; and while doing so, we may sell the Profiled Issuer’s securities we acquired during our public dissemination of the Information causing us to profit while you suffer a loss;
  • Parties holding a Profiled Issuer’s securities, including those who engage our services and/or compensate us, will sell their shares of the Profiled Issuer while we are publishing the (favorable) Information.
Who is responsible if an investor relies on the Information? The investor. We are not responsible or liable for any person’s use of the Information or any success or failure that is directly or indirectly related to such person’s use of the Information because we have specifically stated that the information is not reliable and should not be relied upon for any purpose. We are not responsible for omissions or errors in the Information, and we are not responsible for actions taken by any person who relies upon the Information. What do we urge potential investors to do? We urge Investors to conduct their own in-depth investigation of the Profiled Issuers with the assistance of their legal, tax and investment advisers. An investor’s review of the Information should include but not be limited to the Profiled Issuer’s financial condition, operations, management, products or services, trends in the industry and risks that may be material to the profiled Issuer’s business and other information he and his advisers deem material to an investment decision. An investor’s review should include, but not be limited to a review of available public sources and information received directly from the Profiled Issuers or from websites such as Google, OTC Markets, NASDAQ, NYSE, or other available public sources. Why is this Disclaimer being provided? We are providing you with this disclaimer because we are publishing advertisements about penny stocks. Because we are paid to disseminate the Information to the public about securities, we are required by the securities laws including Section 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 thereunder, and Section 17(b) of the Securities Act of 1933, as amended (the “Securities Act”), to specifically disclose our compensation as well as other important information, This information includes that we may hold, as well as purchase and sell, the securities of a Profiled Issuer before, during and after we publish favorable Information about the Profiled Issuer. We may urge investors to purchase the securities of a Profiled Issuer while we sell our own shares. The anti-fraud provisions of federal and state securities laws require us to inform you that we may engage in buying and selling of Profiled Issuer’s securities before, during and after the Campaigns. What are other risks that investors should be aware of? Any investment in the Profiled Issuers involves a high degree of risk and uncertainty. The securities may be subject to extreme volume and price volatility, especially during the Campaigns. Favorable past performance of a Profiled Issuer does not guarantee future results. If you purchase the securities of the Profiled Issuers, you should be prepared to lose your entire investment. Some of the risks involved in purchasing securities of the Profiled Issuers include, but are not limited to the risks stated below.
  • We do not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information. We conduct no due diligence or investigation whatsoever of the Information or the Profiled Issuers and we do not receive any verification from the Profiled Issuer regarding the Information we disseminate.
  • If we publish any percentage gain of a Profiled Issuer from the previous day close in the Information, it is not and should not be construed as an indication that the future stock price or future operational results will reflect gains or otherwise prove to be advantageous to your investment.
  • The Information may contain statements asserting that a Profiled Issuer’s stock price has increased over a certain period of time which may reflect an arbitrary period of time, and is not predictive or of any analytical quality; as such, you should not rely upon the (favorable) Information in your analysis of the present or future potential of a Profiled Issuer or its securities.
  • The Information should not be interpreted in any way, shape, form or manner whatsoever as an indication of the Profiled Issuer’s future stock price or future financial performance.
  • You may encounter difficulties determining what, if any, portions of the Information are material or non-material, making it all the more imperative that you conduct your own independent investigation of the Profiled Issuer and its securities with the assistance of your legal, tax and financial advisor.
  • We or other stock promoters may receive free trading shares as compensation or we may acquire such shares in open market transactions before and during the Campaigns, and we may sell the shares we acquire at any time, even during the Campaigns while publishing the Favorable Information. When we sell the shares of the Profiled Issuers that we hold, the price at which investors can sell their shares will dramatically decrease and will likely cause investors to suffer trading losses.
  • We may sell securities of the Profiled Issuers for less than target prices set forth in the Information, and we may profit by selling our securities during the Campaigns while investors encounter losses.
  • When we acquire, purchase or sell the securities of the Profiled Issuers, it may (a) cause significant volatility in the Profiled Issuer’s securities; (b) cause temporary but unrealistic increases in volume and price of the Profiled Issuer’s securities; (c) if selling, cause the Profiled Issuer’s stock price to decline dramatically; and (d) permit us to make substantial profits while investors who purchase during the Campaign experience significant losses.
  • The securities of the Profiled Issuers are high risk, unstable, unpredictable and illiquid which may make it difficult for investors to sell their securities of the Profiled Issuers.
  • If we are compensated in improperly free trading securities of the Profiled Issuers, either directly or indirectly from persons who claim to be non-affiliates of such Profiled Issuer, we and the Profiled Issuer or third party could be subject to SEC Enforcement Action, including allegations of an illegal distribution in violation of Section 5(a) and 5(c) of the Securities Act.
  • We may hire third party service providers and stock promoters to electronically disseminate live news regarding the Profiled Issuers, yet we have no control over the content of and do not verify the information that the Profiled Issuers and/or third party service providers publish. These third party service providers are likely compensated for providing positive information about the Issuer and fail to disclose their compensation to you.
If a Profiled Issuer is an SEC reporting company, it could be delinquent (not current) in its periodic reporting obligations (i.e., in its quarterly and annual reports), or if it is an OTC Markets Pink Sheet quoted company, it may be delinquent in its Pink Sheet reporting obligations, which may result in OTC Markets posting a negative legend pertaining to the Profiled Issuer at, as follows: (i) “Limited Information” for companies with financial reporting problems, economic distress, or that are unwilling to file required reports with the Pink Sheets; (ii) “No Information,” which characterizes companies that are unable or unwilling to provide any disclosure to the public markets, to the SEC or the Pink Sheets; and (iii) “Caveat Emptor,” signifying buyers should be aware that there is a public interest concern associated with a company’s illegal spam campaign, questionable stock promotion, known investigation of a company’s fraudulent activity or its insiders, regulatory suspensions or disruptive corporate actions. If the Information states that a Profiled Issuer’s securities are consistent with the future economic trends or even if your independent research indicates that, you should be aware that economic trends have their own limitations, including: (a) that economic trends or predictions may be speculative; (b) consumers, producers, investors, borrowers, lenders and government may react in unforeseen ways and be affected by behavioral biases that we are unable to predict; (c) human and social factors may outweigh future economic trends that we state may or will occur; (d) clear cut economic predictions have their limitations in that they do not account for the fundamental uncertainty in economic life, as well as ordinary life; (e) economic trends may be disrupted by sudden jumps, disruptions or other factors that are not accounted for in economic trends analysis; in other words, past or present data predicting future economic trends may become irrelevant in light of new circumstances and situations in which uncertainty becomes reality rather than predicted economic outcome; or (f) if the trend predicted involves a single result, it ignores other scenarios that may be crucial to make a decision in the event of unknown contingencies. The Information is presented only as a brief snapshot of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities. You should consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at, or other electronic media, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the; (c) obtaining and reviewing publicly available information contained in commonly known search engines such as Google; and (d) consulting investment guides at and You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and the OTC Markets and/or have negative legends and designations at What we were paid to advertise the Profiled Issuers. The details of our compensation and the period of the Campaign is set forth below.
  • Name of Issuer & Ticker Symbol - Grapefruit (GPFT)
  • Amount & Form of Compensation - 180,000 in Common Stock
  • Who Paid for the Campaign & Position with Company if any - Grapefruit (GPFT)
  • Period of Campaign - 11/30/2020 - 11/30/2021
What securities of the Profiled Issuers do we hold? The positions we hold of the Profiled Issuer are set forth below. We plan to sell these securities during the Campaign.
  • Name of Issuer & Ticker Symbol - Grapefruit (GPFT)
  • Number of Shares We or our Affiliates Hold - 6,206,897
  • Price We Paid Per Share - $0
  • Date Issued - 11/16/2020

Related Post

Register for Updates

Go to website
Go to top